LinkedIn Profile

Access Aileron Therapeutics historical Linkedin company profile data on number of followers, employee headcount and more

Rows

Open dataset
Ticker Symbol Entity Name As Of Date Company Name Followers Employees on Linkedin Link Industry Date Added Date Updated Description Website Specialities Logo HQ.Street HQ.City HQ.State HQ.Country HQ.Postal Headcount change in past 24 months Company Name Sector Industry
nasdaq:alrn 508770 Apr 21st, 2024 12:00AM Aileron Therapeutics 7.2K 17.00 Open Apr 20th, 2024 10:49PM Apr 20th, 2024 10:49PM Following the acquisition of Lung Therapeutics in October 2023, Aileron is shifting its disease focus to advancing a pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis diseases, including LTI-03 for idiopathic pulmonary fibrosis (IPF) and LTI-01 for loculated pleural effusion (LPE). For more information about the company, please visit our website. Open Drug Development, Stapled Peptides, Biopharmaceuticals, Chemistry, Chemoprotection, Myelopreservation, Chemotherapy, and Supportive Care Open 285 Summer Street Boston MA US 02210 Aileron Therapeutics
nasdaq:alrn 508770 Apr 20th, 2024 12:00AM Aileron Therapeutics 7.2K 17.00 Open Apr 19th, 2024 10:39PM Apr 20th, 2024 04:31PM Following the acquisition of Lung Therapeutics in October 2023, Aileron is shifting its disease focus to advancing a pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis diseases, including LTI-03 for idiopathic pulmonary fibrosis (IPF) and LTI-01 for loculated pleural effusion (LPE). For more information about the company, please visit our website. Open Drug Development, Stapled Peptides, Biopharmaceuticals, Chemistry, Chemoprotection, Myelopreservation, Chemotherapy, and Supportive Care Open 285 Summer Street Boston MA US 02210 Aileron Therapeutics
nasdaq:alrn 508770 Apr 19th, 2024 12:00AM Aileron Therapeutics 7.2K 17.00 Open Apr 18th, 2024 10:47PM Apr 18th, 2024 10:47PM Following the acquisition of Lung Therapeutics in October 2023, Aileron is shifting its disease focus to advancing a pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis diseases, including LTI-03 for idiopathic pulmonary fibrosis (IPF) and LTI-01 for loculated pleural effusion (LPE). For more information about the company, please visit our website. Open Drug Development, Stapled Peptides, Biopharmaceuticals, Chemistry, Chemoprotection, Myelopreservation, Chemotherapy, and Supportive Care Open 285 Summer Street Boston MA US 02210 Aileron Therapeutics
nasdaq:alrn 508770 Apr 18th, 2024 12:00AM Aileron Therapeutics 7.2K 17.00 Open Apr 17th, 2024 10:50PM Apr 18th, 2024 05:51PM Following the acquisition of Lung Therapeutics in October 2023, Aileron is shifting its disease focus to advancing a pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis diseases, including LTI-03 for idiopathic pulmonary fibrosis (IPF) and LTI-01 for loculated pleural effusion (LPE). For more information about the company, please visit our website. Open Drug Development, Stapled Peptides, Biopharmaceuticals, Chemistry, Chemoprotection, Myelopreservation, Chemotherapy, and Supportive Care Open 285 Summer Street Boston MA US 02210 Aileron Therapeutics
nasdaq:alrn 508770 Apr 17th, 2024 12:00AM Aileron Therapeutics 7.2K 17.00 Open Apr 16th, 2024 10:37PM Apr 17th, 2024 02:15PM Following the acquisition of Lung Therapeutics in October 2023, Aileron is shifting its disease focus to advancing a pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis diseases, including LTI-03 for idiopathic pulmonary fibrosis (IPF) and LTI-01 for loculated pleural effusion (LPE). For more information about the company, please visit our website. Open Drug Development, Stapled Peptides, Biopharmaceuticals, Chemistry, Chemoprotection, Myelopreservation, Chemotherapy, and Supportive Care Open 285 Summer Street Boston MA US 02210 Aileron Therapeutics
nasdaq:alrn 508770 Apr 16th, 2024 12:00AM Aileron Therapeutics 7.2K 17.00 Open Apr 15th, 2024 10:36PM Apr 16th, 2024 10:31AM Following the acquisition of Lung Therapeutics in October 2023, Aileron is shifting its disease focus to advancing a pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis diseases, including LTI-03 for idiopathic pulmonary fibrosis (IPF) and LTI-01 for loculated pleural effusion (LPE). For more information about the company, please visit our website. Open Drug Development, Stapled Peptides, Biopharmaceuticals, Chemistry, Chemoprotection, Myelopreservation, Chemotherapy, and Supportive Care Open 285 Summer Street Boston MA US 02210 Aileron Therapeutics
nasdaq:alrn 508770 Apr 15th, 2024 12:00AM Aileron Therapeutics 7.2K 17.00 Open Apr 14th, 2024 10:38PM Apr 15th, 2024 04:12PM Following the acquisition of Lung Therapeutics in October 2023, Aileron is shifting its disease focus to advancing a pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis diseases, including LTI-03 for idiopathic pulmonary fibrosis (IPF) and LTI-01 for loculated pleural effusion (LPE). For more information about the company, please visit our website. Open Drug Development, Stapled Peptides, Biopharmaceuticals, Chemistry, Chemoprotection, Myelopreservation, Chemotherapy, and Supportive Care Open 285 Summer Street Boston MA US 02210 Aileron Therapeutics
nasdaq:alrn 508770 Apr 14th, 2024 12:00AM Aileron Therapeutics 7.2K 17.00 Open Apr 13th, 2024 10:32PM Apr 13th, 2024 10:32PM Following the acquisition of Lung Therapeutics in October 2023, Aileron is shifting its disease focus to advancing a pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis diseases, including LTI-03 for idiopathic pulmonary fibrosis (IPF) and LTI-01 for loculated pleural effusion (LPE). For more information about the company, please visit our website. Open Drug Development, Stapled Peptides, Biopharmaceuticals, Chemistry, Chemoprotection, Myelopreservation, Chemotherapy, and Supportive Care Open 285 Summer Street Boston MA US 02210 Aileron Therapeutics
nasdaq:alrn 508770 Apr 13th, 2024 12:00AM Aileron Therapeutics 7.2K 16.00 Open Apr 12th, 2024 10:23PM Apr 13th, 2024 10:59AM Following the acquisition of Lung Therapeutics in October 2023, Aileron is shifting its disease focus to advancing a pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis diseases, including LTI-03 for idiopathic pulmonary fibrosis (IPF) and LTI-01 for loculated pleural effusion (LPE). For more information about the company, please visit our website. Open Drug Development, Stapled Peptides, Biopharmaceuticals, Chemistry, Chemoprotection, Myelopreservation, Chemotherapy, and Supportive Care Open 285 Summer Street Boston MA US 02210 Aileron Therapeutics
nasdaq:alrn 508770 Apr 12th, 2024 12:00AM Aileron Therapeutics 7.2K 16.00 Open Apr 11th, 2024 10:26PM Apr 12th, 2024 07:54AM Following the acquisition of Lung Therapeutics in October 2023, Aileron is shifting its disease focus to advancing a pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis diseases, including LTI-03 for idiopathic pulmonary fibrosis (IPF) and LTI-01 for loculated pleural effusion (LPE). For more information about the company, please visit our website. Open Drug Development, Stapled Peptides, Biopharmaceuticals, Chemistry, Chemoprotection, Myelopreservation, Chemotherapy, and Supportive Care Open 285 Summer Street Boston MA US 02210 Aileron Therapeutics

Request a demo to view additional historical data, and much more.

Request Demo

Make fast
queries

No longer rely on engineers to access data; build and share queries with intuitive tools, and derive insights in real time.

Bookmark queries with your team

Save and share custom queries using a private bookmarking feature, accessible to your whole team.

Be first to know with alerts

Scan data points across millions of companies and receive emails when relevant metrics cross critical thresholds.

Visualize data for quick insights

Create custom keyword-based word clouds, charts, and advanced visualizations to quickly analyze the data.

Map competitor locations

Analyze competitor presence and growth over time by overlaying store locations with the Nearby Competitor feature.

Add widgets to your dashboards

Access existing maps, charts, word clouds, and other visualizations to understand your data quickly. Or build custom widgets to view data just the way you want it.